R&D channel feed – Endpoints News

R&D channel feed

A treasure trove of new leads on drug targets and biomarkers has been uncovered in a huge proteomics study

Last year

Lilly says about 70% of patients taking tirzepatide experienced an adverse event

Last year

Neurocrine reports a second PhIII success in congenital adrenal hyperplasia, this time in children

Last year

Longeveron touts PhIIa Alzheimer's data, but drug's future remains murky

Last year

UniQure halves research, lays off 20% while CSO departs in major revamp

Last year

Kezar changes CEOs, lays off 41% of staff and halts preclinical R&D to extend cash runway

Last year

Moderna eyes PhIII start for combo mRNA jab targeting Covid and flu after PhI/II success

Last year

GLP-1 gene therapy triggers 25% weight loss in obese mice, clinical trials planned for next year

Last year

Vertex says another type 1 diabetes patient is insulin-free in updated data out of EASD

Last year

BridgeBio partners with biomanufacturer Resilience to produce early-stage AAV gene therapies

Last year

Exscientia ends cancer study as it focuses on other trials of AI-driven drug candidates

Last year

Updated: In turnaround, ALX Oncology’s CD47 blocker shows efficacy in gastric cancer trial

Last year

Novartis to seek accelerated approval for oral complement inhibitor in rare kidney disease

Last year

Syros lays off 35% of workers, replaces CEO and loses CSO after axed pacts

Last year

Exclusive: 'Faster isn't better' — Atomwise moves from partnerships to pipeline with TYK2 drug

Last year

Corrected: Syndax stops PhI/II leukemia study early after menin inhibitor shows efficacy in challenging mutation

Last year

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Last year

Structure Therapeutics 'encouraged' by 5.4% weight loss with its oral GLP-1, plans for more studies

Last year

Bionomics’ stock skyrockets 340% after PTSD candidate passes PhIIb test

Last year

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Last year

German radiopharma Ariceum unveils early efficacy signal for lead asset in neuroendocrine cancers

Last year

Gritstone inks up to $433M contract with BARDA for 10,000-person Covid-19 vaccine trial

Last year

Biden administration doles out $100M to research drug-resistant infections

Last year

Amgen readies PhIII trial for first Opdivo biosimilar, with launch unlikely before 2028

Last year

First page Previous page 69 70 717273 74 75 Next page Last page